Syngensys key facts
as of Oct 2026- Developer of a synthetic biology platform designed to provide the design and manufacturing of next-generation biomedicines and bioprocesses.
- Syngensys is valued at approximately $8.6M as of Oct 2026 (last reported valuation).
- It has raised $4.1M; the latest was Seed Round ($4.1M) in Apr 2025.
- Notable investors include Takeda Ventures, The University of Sheffield.
- Status: Privately Held (backing).
Syngensys's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch Syngensys: the Monday email on marks, rounds and moves
Syngensys funding rounds
No funding rounds for Syngensys are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Syngensys
2Syngensys valuation
Syngensys's last reported valuation was $8.6 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Syngensys investors
2 investors are on record for Syngensys, including Takeda Ventures and The University of Sheffield.
About Syngensys
Developer of a synthetic biology platform designed to provide the design and manufacturing of next-generation biomedicines and bioprocesses. The company offers product-specific libraries of synthetic genetic parts with the ability to engineer novel synthetic genetic parts from the ground up, based on bioinformatic analysis of streams of genome-scale information pertinent to the biological system and user-defined design criteria, enabling clients to design and manufacture novel biomolecules with desired properties.
- Sector
- Healthcare
- HQ
- Sheffield, United Kingdom
- Founded
- 2021
- Employees
- 14
- Website
- syngensys.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.